Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial - Diabetologia Aims/hypothesis We aimed to investigate canagliflozin’s effects on myocardial fibrosis, cardiac structure and function, and microcirculation in high-cardiovascular-risk type 2 diabetes mellitus throug...

Novel RCT: Canagliflozin reduces myocardial fibrosis (by CMR) in high-risk #T2DM, providing imaging evidence for its cardioprotection. A mechanism beyond glycaemic management. #SGLT2i #CardioDiabetes #HeartFailure #DiabetesResearch link.springer.com/article/10.1... 🔓

How To Treat Cardiovascular Disease in People with Diabetes - Blog - NIDDK Dr. Brendan M. Everett shares key strategies for treating heart disease in people with diabetes, including when to refer to a cardiologist and medication risks.

Beyond A1C.
GLP-1s and SGLT2s are game-changers in #CVD risk reduction for #diabetes patients.

Learn more: www.niddk.nih.gov/health-infor...

#MMPC #GLP1 #SGLT2 #CardioDiabetes

How To Treat Cardiovascular Disease in People with Diabetes - Blog - NIDDK Dr. Brendan M. Everett shares key strategies for treating heart disease in people with diabetes, including when to refer to a cardiologist and medication risks.

CVD risk isn’t a side note in #diabetes care—it’s the main story.

📚 Read NIDDK’s treatment guidance: www.niddk.nih.gov/health-infor...
#MMPC #MetabolicCare #CardioDiabetes